The Inmazeb Injection, cataloged under National Stock Number 6505-01-693-8769, is classified within Federal Supply Class 6505 (Drugs and Biologicals) of the Medical, Dental, and Veterinary Equipment group. The manufacturer of record is Regeneron Pharmaceuticals Inc. The record lists 1 manufacturer part number for this item, enabling identification through both NSN and commercial part number lookups. 2 additional reference documents (drawings, advisory and superseded references) are recorded in the U.S. Government catalog. Current acquisition status: Active. Unit of issue: EA.
| Parameter | Value |
|---|---|
| NSN | 6505-01-693-8769 |
| Primary Part Number | NDC61755-0018-01 |
| Item Name | Inmazeb Injection |
| FSC / FSG | 6505 / 65 — Drugs and Biologicals |
| Manufacturer | Regeneron Pharmaceuticals Inc |
| Status | ACTIVE |
| Acquisition Status | ACTIVE |
| DEMIL Code | DEMIL A — No Demilitarization Required |
| Hazard | Possible hazard — SDS may be required (DLA HMIC P) |
| Criticality Code | X |
| Unit of Issue | EA |
| Part Number | Manufacturer |
|---|---|
| NDC61755-0018-01 PRIMARY | Regeneron Pharmaceuticals Inc (USA) |
| Reference | Meaning |
|---|---|
| 1590737 | 5/1 Secondary reference U.S. Government activity |
| 6505NCM216892 | 5/1 Secondary reference Defense Medical Standardization Board |
NSN 6505-01-693-8769 is a Inmazeb Injection, manufactured by Regeneron Pharmaceuticals Inc, classified under FSC 6505, Drugs and Biologicals. Status: active.
NSN 6505-01-693-8769 has 1 manufacturer part number on file: NDC61755-0018-01 (Regeneron Pharmaceuticals Inc).
Key specifications for NDC61755-0018-01: Special Features: ATOLTIVIMAB, MAFTIVIMAB,AND ODESIVIMAB EBGN) INJECTION 241.7 MG / 241.7 MG / 241.7 MG PER 14.5 ML. SINGLE DOSE VIAL. INDICATED FOR THE TREATMENT OF INFECTION CAUSED BY ZAIRE EBOLAVIRUS IN ADULT AND PEDIATRIC PATIENTS, INCLUDING NEONATES; TREATMENT IS MOST EFFECTIVE WHEN GIVEN EARLY IN THE COURSE OF THE DISEASE; INMAZEB (ATOLTIVIMAB, MAFTIVIMAB & ODESIVIMAB-EBGN) IS A NOVEL ANTIBODY MEDICINE; INMAZEB IS ADMINISTERED AS A SINGLE, WEIGHT BASED INTRAVENOUS INFUSION; REFRIGERATE AT 2 TO 8 DEGREES CELSIUS( 36F TO 46F) IN THE ORIGINAL CARTON TO PROTECT FROM LIGHT; DO NOT FREEZE OR SHAKE; DOES NOT CONTAIN PRESERVATIVES; SINGLE DOSE VIAL.; Part Name Assigned by Controlling Agency: INMAZEB INJECTION SOLUTION, VIAL. 0 specifications are documented in the U.S. Government catalog.
Possible hazard — SDS may be required (DLA HMIC P). Hazard information on this page is shown exactly as it appears in the DLA record.
U.S. Government catalog: edition PUBLOGDVD v12.0.0 (OCT 2026), edition date 2026-10-01, retrieved 2026-10-16.
U.S. Government catalog: edition PUBLOGDVD v12.0.0 (OCT 2026), edition date 2026-10-01, retrieved 2026-10-18.